Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

14.80 +0.45 (+3.14%)
Streaming Delayed Price Updated: 10:05 AM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 190,126
Open 14.68
Bid (Size) 14.79 (6)
Ask (Size) 14.81 (2)
Prev. Close 14.35
Today's Range 14.55 - 14.81
52wk Range 13.40 - 20.68
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-20.7%
-20.7%
1 Month
-14.1%
-14.1%
3 Month
-17.3%
-17.3%
6 Month
+1.9%
+1.9%
1 Year
-12.9%
-12.9%

More News

Read More
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
NASDAQ:ACAD, an undervalued stock with good fundamentals.
Via Chartmill
While growth is established for NASDAQ:ACAD, the stock's valuation remains reasonable.
Via Chartmill
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
From Acadia Pharmaceuticals Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet
Via Benzinga
Exposures Fossil Fuels
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
From Acadia Pharmaceuticals
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711
From Acadia Pharmaceuticals Inc.
Via Business Wire

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 14.80
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 04/23/25 10:05 AM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 2.41B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.